23 completed, 17 recruiting, 7 active not recruiting, 6 terminated. 40 Phase 2, 20 Phase 1, 7 Phase 3, 2 Not applicable, 2 Phase 4.
Follow this drug Literature Review of Inotuzumab Ozogamicin trials Research Report on Inotuzumab Ozogamicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin (IO) - Acute Lymphobkastic Leukemia, Adult | Phase 2 | Not yet recruiting | PETHEMA Foundation | 30 | 2026-10-30 | 2026-10-07 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-10-01 | 2026-08-18 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL Olverembatinib, Venetoclax, Blinatumomab - Ph+ ALL | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 110 | 2026-04-10 | 2026-07-23 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 750 | 2026-04-01 | 2026-03-17 |
| Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 28 | 2025-05-21 | 2026-02-18 |
| Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Blinatumomab and Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2025-05-17 | 2026-03-24 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Dexamethasone, Blinatumomab, Venetoclax - Precursor B-Cell Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 20 | 2024-08-15 | 2024-08-15 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD - Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-11 | 2026-08-10 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Vincristine, Cyclophosphamide, Dexamethasone - Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2024-04-02 | 2025-12-17 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Cyclophosphamide, Vincristine, Blinatumomab - Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 27 | 2023-07-14 | 2026-09-23 |
| Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 68 | 2023-06-09 | 2026-07-10 |
| A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Inotuzumab ozogamicin, ALLR3 - ACUTE LYMPHOBLASTIC LEUKEMIA | Phase 2 | Recruiting | Pfizer | 100 | 2023-05-17 | 2026-09-24 |
| A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment Inotuzumab Ozogamicin - Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | Completed | Pfizer | 32 | 2023-03-08 | 2025-02-04 | |
| A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia inotuzumab ozogamicin - Acute Lymphoblastic Leukemia | Phase 4 | Completed | Pfizer | 44 | 2023-02-24 | 2025-12-03 |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive the usage of Olverembatinib combined with Inotuzumab Ozogamicin - Ph+ ALL, Bone Marrow Transplant | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 46 | 2022-10-30 | 2022-11-02 |
Showing 20 of 66. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Burkitt Lymphoma (23) · Lymphoma, B-Cell (7) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (7) · Recurrence (6) · Lymphoma (5) · Leukemia (4) · Lymphoma, Large B-Cell, Diffuse (4) · Hematologic Neoplasms (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma, Non-Hodgkin (2) · Blast Crisis (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1)
Pfizer (17) · M.D. Anderson Cancer Center (11) · Institute of Hematology & Blood Diseases Hospital, China (8) · Alliance for Clinical Trials in Oncology (2) · Children's Oncology Group (2) · St. Jude Children's Research Hospital (2) · BeOne Medicines (1) · Charite University, Berlin, Germany (1) · Children's Hospital Medical Center, Cincinnati (1) · Cristiana Sessa (1) · Dana-Farber Cancer Institute (1) · First Affiliated Hospital of Zhejiang University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Leland Metheny (1) · National Cancer Institute (NCI) (1)
United States (36) · China (12) · France (10) · Belgium (9) · Germany (9) · Spain (9) · United Kingdom (8) · South Korea (7) · Canada (6) · Italy (6) · Poland (6) · Singapore (6) · Hungary (5) · Japan (5) · Netherlands (5)
Elias Jabbour (4) · Elias Jabbour, MD (2) · Anastasios Stathis, Dr. (1) · Andrew McMillan (1) · Anjali Advani (1) · Arend Elisabeth von Stackelberg, Dr. med., MD (1) · David McCall, MD (1) · Eunice S Wang (1) · Fabio Ciceri (1) · Giovanni Martinelli (1) · Hagop Kantarjian, MD (1)
PMID 41671463, PMID 35622074, PMID 38551807, PMID 33231879, PMID 20491780, PMID 22335424, PMID 22357140, PMID 23295790, PMID 27154915, PMID 27292104, PMID 28687420, PMID 28859185, PMID 28959500, PMID 29296758, PMID 29330398, PMID 29352703, PMID 29381191, PMID 30920645, PMID 31655984, PMID 31790983, PMID 32589970, PMID 32769965, PMID 33191168, PMID 33602684, PMID 34407735, PMID 35007127, PMID 35643855, PMID 36279879, PMID 37131217, PMID 37187201, PMID 37879077, PMID 37883727, PMID 38170741, PMID 38607410, PMID 38722664, PMID 39418626, PMID 39882642, PMID 41026957, PMID 42789493
U10CA180821 (3), 2008 (2), 2018 (2), 2023 (2), P30CA016672 (2), U10CA180886 (2), 2005 (1), 2009 (1), 2016 (1), U10CA032102 (1), U10CA180888 (1)